The emerging role of subclinical inflammation in hypertension-associated early renal dysfunction: Focus on microalbuminuria

Hellenic Journal of Cardiology

Volumn 47, Issue 6, 2006, Pages 361-365

  Tsioufis, Costas ^a,b   Dimitriadis, Kyriakos ^a   Stefanadis, Christodoulos ^a   Kallikazaros, Ioannis ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Hypertension; Inflammation; Microalbuminuria

Indexed keywords

ADIPONECTIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG MECHANISM; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; HOSPITAL CARE; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY DYSFUNCTION; MICROALBUMINURIA; MORTALITY; PREVALENCE; REVIEW; ALBUMINURIA; DISEASE COURSE; KIDNEY DISEASE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RENOVASCULAR HYPERTENSION; TIME;

ALBUMINURIA; DISEASE PROGRESSION; HUMANS; HYPERTENSION, RENAL; INFLAMMATION; KIDNEY DISEASES; TIME FACTORS;

EID: 34247145559     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Pedrinelli R, Dell' Omo G, Di Bello V, et al: Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 2002; 16: 79-88.
2. Ruilope LM: The kidney as a sensor of cardiovascular risk in essential hypertension. J Am Soc Nephrol 2002; 13: S165-S168.
3. Pontremolli R, Sofia A, Ravera M, et al: Prevalence and clinical correlates of microalbuminuria in essential hypertension. The MAGIC study. Hypertension 1997; 30: 1135-1143.
4. Geirstein H, Mann J, Qilong Yi, et al: Albuminuria and risk of cardiovascular events and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
5. Jager A, Kostense P, Ruhe H, et al: Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects. Five years follow-up of the Hoorn study. Arterioscler Thromb Vasc Biol 1999; 19: 617-624.
6. Diercks GF, Hillege HL, van Boven AJ, et al: Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes. J Am Coll Cardiol 2002; 40: 1401-1407.
7. Berton G, Cordiano R, Palmieri R, et al: Microalbuminuria during acute myocardial infarction; a strong predictor for 1-year mortality. Eur Heart J 2001; 22: 1466-1475.
8. Tsioufis C, Dimitriadis K, Antoniadis D, et al: Inter-relationships of microalbuminuria with the other surrogates of the atherosclerotic cardiovascular disease in hypertensive subjects. Am J Hypertens 2004; 17: 470-476.
9. Wachtell K, Palmieri V, Olsen MH, et al: Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J 2002; 143: 319-326.
10. Palaniappan L, Carnethon M, Fortmann S: Association between microalbuminuria and the metabolic syndrome: NHANES II. Am J Hypertens 2003; 16: 952-958.
11. Tsioufis C, Stefanadis C, Toutouza M, et al: Microalbuminuria is associated with unfavourable cardiac geometric adaptations in essential hypertensive subjects. J Hum Hypertens 2002; 16: 249-254.
12. Campese VM, Bianchi S, Bigazzi R: Association between hyperlipidemia and microalbuminuria in essential hypertension. Kidney Int 1999; 56: S10-S13.
13. Tsioufis C, Lambrou S, Antoniadis D, et al: Microalbuminuria is associated with more impaired thoracic aortic elastic properties. Hellenic J Cardiol 2001; 42: 244-254.
14. Kuusisto J, Mykkanen L, Pyorala K, et al: Hyperinsulinemic microalbuminuria. A new risk indicator for coronary heart disease. Circulation 1995; 91: 831-837.
15. Yudkin JS: Hyperinsulinaemia, insulin resistance, microalbuminuria and the risk of coronary heart disease. Ann Med 1996; 28: 433-438.
16. Tsioufis C, Tzioumis C, Marinakis N, et al: Microalbuminuria is closely related to impaired arterial elasticity in untreated patients with essential hypertension. Nephron Clin Pract 2003; 93: 106-111.
17. Sesso HD, Buring JE, Rifai N, et al: C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-2951.
18. Schillaci G, Pirro M, Gemelli F, et al: Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens 2003; 21: 1841-1846.
19. Chae Claudia, Lee R, Rifai N, et al: Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38: 399-403.
20. Stuveling EM, Bakker SJ, Hillege HL, et al: PREVEND Study Group: C-reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension 2004; 43: 791-796.
21. Bermudez EA, Rifai N, Buring J, et al: Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002; 22: 1668-1673.
22. Engstrom G, Janson L, Berglund G, et al: Inflammation-sensitive plasma proteins and incidence of myocardial infarction in men with low cardiovascular risk. Arterioscler Thromb Vasc Biol 2003; 23: 2247-2251.
23. Griendling K, Sorescu D, Lassegue B, et al: Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Artersiocler Thromb Vasc Biol 2000; 20: 2175-2183.
24. Dzau VJ: Angiotensin and pathophysiology of vascular disease: A unifying hypothesis. Hypertension 2001; 37: 1047-1052.
25. Kuwahara F, Kai H, Niiyama H, et al: Roles of intercellular adhesion, molecule-1 in hypertensive cardiac remodeling. Hypertension 2003; 41: 819-823.
26. Mann DI: Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circ Res 2002; 91: 988-998.
27. Bigazzi R, Bianchi S, Baldari D, et al: Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16: 1325-1333.
28. Bianchi S, Bigazzi R, Campese MV: Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis 1999; 34: 973-995.
29. Dell'Omo G, Penno G, Giorgi D, et al: Pedrinelli R: Association of high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men. Am J Kidney Dis 2002; 40: 1-8.
30. Klausen KP, Scharling H, Jensen G, et al: New definition of microalbuminuria in hypertensive subjects. Association with incident coronary heart disease and death. Hypertension 2005; 46: 33-37.
31. Skov Jensen J, Feldt-Rasmussen B, Strandgaard S, et al: Arterial hypertension, microalbuminuria and risk of ischemic heart disease. Hypertension 2000; 35: 898-903.
32. Mogensen CE: Systemic blood pressure and glomerular leakage with particular reference to diabetes and hypertension. J Intern Med 1994; 235: 297-316.
33. Brasier A, Recinos A, Eledrisi M: Vascular inflammation and the renin-angiotensin system. Artertioscler Thromb Vasc Biol 2002; 22: 1257-1266.
34. Berton G, Citro T, Palmieri R, et al: Albumin excretion rate is increased during acute myocardial infarction and strongly predicts early mortality. Circulation 1997; 96: 3338-3345.
35. Gosling P, Hughes EA, Reynolds JP, et al: Microalbuminuria is an early response following acute myocardial infarction. Eur Heart J 1991; 12: 508-513.
36. Jager A, van Hinsbergh VW, Kostense PJ, et al: C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol 2002; 22: 593-598.
37. Pannaciulli N, Cantatore FP, Minenna A, Belacicco M, Giorgino R, De Pergola G: Urinary albumin excretion is independently associated with C-reactive protein levels in overweight and obese non-diabetic premenopausal women. J Int Med 2001; 250: 502-507.
38. Stehouwer CD, Gall MA, Twisk JW, et al: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes. Diabetes 2002; 51: 1157-1165.
39. Festa A, D'Agostino R, Howard G, et al: Inflammation and microalbuminuria in non-diabetic and type 2 diabetic subjects: The insulin Resistance Atherosclerosis Study. Kidney Int 2000; 58: 1703-1710.
40. Dimitriadis K, Tsioufis C, Chatzis D, et al: Plasma levels of C-reactive protein are associated with early renal dysfunction in newly diagnosed essential hypertensive patients. Circulation 2004; 110: III-232 (1113).
41. Dimitriadis K, Tsioufis C, Kaltsi I, et al: Early renal dysfunction is associated with hypoadiponectinemia and subclinical inflammation in essential hypertensive subjects. J Am Coll Cardiol 2005; 45 (suppl A): 426 A (1155-103).
42. Szmitko P, Wang C, Weisel R, et al: New markers of inflammation and endothelial cell activation. Circulation 2003; 108: 1917-1923.
43. Luft F: Mechanisms and cardiovascular damage in hypertension. Hypertension 2003; 37: 594-598.
44. Ibsen H, Olsen MH, Wachtell K, et al: Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198-202.
45. Das UN: Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit 2005; 11: 155-162.
46. Volpe M, Ruilope LM, McInnes GT, et al: Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? J Hum Hypertens 2005; 19: 331-339.
47. Ouchi N, Kihara S, Funahashi T, et al: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107: 671-674.
48. Tsioufis C, Dimitriadis K, Chatzis D, et al: Relation of microalbuminuria to diponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol 2005; 96: 946-951.
49. Barzilay JI, Peterson D, Cushman M, et al: The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular risk study. Am J Kidney Dis 2004; 44: 25-34.
50. Pedrinelli R, Dell'Omo G, Di Bello V, et al: Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol 2004; 24: 2414-2419.
51. Stuveling EM, Hillege HL, Bakker SJ, et al; PREVEND study group: C-reactive protein and microalbuminuria differ in their associations with various domains of vascular disease. Atherosclerosis 2004; 172: 107-114.
52. Tsioufis C, Stougiannos P, Kakkavas A, et al: Relation of left ventricular concentric remodeling to levels of C-reactive protein and serum amyloid a in patients with essential hypertension. Am J Cardiol 2005; 96: 252-256.
53. Tsioufis C, Dimitriadis K, Taxiarchou E, et al: Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. Am J Hypertens 2006; 19: 462-466.
54. Aukrust P, Muller F, Ueland T, et al: Enhanced levels of soluble and membrane-bound CD 40 ligand in patients with unstable angina. Circulation 1999; 100: 614-620.
55. Blankenberg S, Ducimetiere P, Arveiler D, et al: Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003; 108: 2453-2459.